- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01247545
Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in CABG Surgery (ERICCA)
Effect of Remote Ischaemic Preconditioning on Clinical Outcomes in Coronary Artery Bypass Graft Surgery
Coronary heart disease (CHD) is the leading cause of death in the UK, accounting for 124,000 deaths (2006) and costing the UK economy over £7.9 billion a year. Patients with severe CHD are usually treated by coronary artery bypass graft (CABG) surgery, the risks of which are increasing due to older and sicker patients being operated on. New treatment strategies are therefore required to improve health outcomes in these high-risk patients undergoing CABG with or without valve (CABG±valve) surgery.
The hypothesis tested in this research proposal is that remote ischaemic preconditioning (RIC), a virtually cost-free, non-pharmacological and simple non-invasive strategy for reducing the damage to the heart muscle at the time of surgery, improves health outcomes in high-risk patients undergoing CABG±valve surgery.
In this research project, 1610 high-risk patients undergoing CABG±valve surgery will be recruited via 28 UK hospitals performing heart surgery. Patients will be randomly allocated to receive either RIC or control. For RIC, a blood pressure cuff will be placed on the upper arm to temporarily deprive it of oxygen and nutrients, an intervention which has been shown in the investigators pilot studies to reduce damage to the heart muscle by up to 40% during CABG±valve surgery. The investigators will determine whether RIC can improve health outcomes in terms of better patient survival, less heart attacks and strokes, shorter hospital stay; less damage to the heart, kidney and brain during surgery; better heart function post-surgery and less chance of developing heart failure; better exercise tolerance and quality of life.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Blackpool, Royaume-Uni
- Blackpool Victoria Hospital
-
Cambridge, Royaume-Uni
- Papworth Hospital
-
Cardiff, Royaume-Uni
- Cardiff & Vale University Health Board
-
Edinburgh, Royaume-Uni
- Edinburgh Royal Infirmary
-
Glasgow, Royaume-Uni
- Golden Jubilee Hospital
-
Harefield, Royaume-Uni
- Harefield Hospital
-
Hull, Royaume-Uni
- Castle Hill Hospital
-
Leicester, Royaume-Uni
- Glenfield Hospital
-
London, Royaume-Uni
- Royal Brompton Hospital
-
London, Royaume-Uni
- St George's Hospital
-
London, Royaume-Uni
- Hammersmith Hospital
-
London, Royaume-Uni
- St Bartholomew's Hospital
-
London, Royaume-Uni
- St Thomas Hospital
-
London, Royaume-Uni
- Kings College London Hospital
-
London, Royaume-Uni
- London Chest Hospital
-
London, Royaume-Uni
- UCLH Heart Hospital
-
Manchester, Royaume-Uni
- Manchester Royal Infirmary
-
Manchester, Royaume-Uni
- Wythenshawe Hospital
-
Manchester, Royaume-Uni
- John Radcliffe Hospital
-
Newcastle, Royaume-Uni
- Freeman Hospital
-
Nottingham, Royaume-Uni
- Trent Cardiac Centre
-
Plymouth, Royaume-Uni
- Derriford Hospital
-
Sheffield, Royaume-Uni
- Northern General Hospital
-
Southampton, Royaume-Uni
- Southampton General Hospital
-
Swansea, Royaume-Uni
- Swansea Hospital
-
Wolverhampton, Royaume-Uni
- Wolverhampton Hospital
-
-
Essex
-
Basildon, Essex, Royaume-Uni
- Essex cardiothoracic centre
-
-
Sussex
-
Brighton, Sussex, Royaume-Uni
- Royal Sussex County Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients undergoing CABG with or without valve surgery using blood cardioplegia
- Patients aged 18 years and above
- Patients with an additive Euroscore greater than or equal to 5
Exclusion Criteria:
- Cardiogenic shock
- Cardiac arrest on current admission
- Pregnancy
- Significant peripheral arterial disease affecting the upper limbs
- Patients with significant hepatic dysfunction (Prothrombin>2.0 ratio)
- Patients with significant pulmonary disease (FEV1<40% predicted)
- Patients with known renal failure with a GFR<30 mL/min/1.73 m2
- Patients on glibenclamide or nicorandil, as these medications may interfere with RIC
- Patients recruited into another study which may impact on the ERICCA study
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur placebo: Control
Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm.
The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
|
Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm.
The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
|
|
Comparateur actif: Remote ischaemic conditioning
Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
|
Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major adverse cardiac and cerebral events
Délai: One year post-surgery
|
Combined endpoint of Cardiovascular death, MI, Revascularisation and Stroke.
|
One year post-surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Peri-operative myocardial injury
Délai: 72 hours peri-operative period
|
72 hours area under curve serum troponin-T
|
72 hours peri-operative period
|
|
LV ejection fraction
Délai: At one year
|
Echo determined LV ejection fraction
|
At one year
|
|
Acute kidney injury
Délai: Peri-operative
|
Acute kidney injury score and 24 hour area under curve serum NGAL
|
Peri-operative
|
|
30 day MACCE
Délai: 30 days post surgery
|
Major adverse cardiac and cerebral events 30 days post surgery
|
30 days post surgery
|
|
All cause death
Délai: 1 year post surgery
|
1 year post surgery
|
|
|
Length of ITU stay
Délai: ITU stay
|
ITU stay
|
|
|
Length of hospital stay
Délai: Until hospital discharge
|
Until hospital discharge
|
|
|
Inotrope score
Délai: 72 hours post surgery
|
Inotrope score after 72 hours
|
72 hours post surgery
|
|
6 minute Walk Test
Délai: 6 weeks and 12 months post surgery
|
6 weeks and 12 months post surgery
|
|
|
Quality of Life
Délai: 6 weeks, 3/6/9 and 12 months post surgery
|
Quality of Life assessed using the EQ-5D measurement
|
6 weeks, 3/6/9 and 12 months post surgery
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Derek J Hausenloy, MD PhD, University College, London
Publications et liens utiles
Publications générales
- Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9. doi: 10.1016/S0140-6736(07)61296-3.
- Venugopal V, Laing CM, Ludman A, Yellon DM, Hausenloy D. Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis. 2010 Dec;56(6):1043-9. doi: 10.1053/j.ajkd.2010.07.014. Epub 2010 Oct 25.
- Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res. 2008 Aug 1;79(3):377-86. doi: 10.1093/cvr/cvn114. Epub 2008 May 2.
- Candilio L, Malik A, Ariti C, Barnard M, Di Salvo C, Lawrence D, Hayward M, Yap J, Roberts N, Sheikh A, Kolvekar S, Hausenloy DJ, Yellon DM. Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. Heart. 2015 Feb;101(3):185-92. doi: 10.1136/heartjnl-2014-306178. Epub 2014 Sep 24.
- Venugopal V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, Lawrence D, Bognolo J, Yellon DM. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. Heart. 2009 Oct;95(19):1567-71. doi: 10.1136/hrt.2008.155770. Epub 2009 Jun 8.
- Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, Pepper J, Robertson S, Xenou M, Clayton T, Yellon DM; ERICCA Trial Investigators. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med. 2015 Oct 8;373(15):1408-17. doi: 10.1056/NEJMoa1413534. Epub 2015 Oct 5.
- Hausenloy DJ, Candilio L, Laing C, Kunst G, Pepper J, Kolvekar S, Evans R, Robertson S, Knight R, Ariti C, Clayton T, Yellon DM; ERICCA Trial Investigators. Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol. 2012 May;101(5):339-48. doi: 10.1007/s00392-011-0397-x. Epub 2011 Dec 21.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 10/0303
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .